Free Trial Information
BioCentury | Jun 8, 2015
Strategy

Juno's progressive thinking

...Kite Pharma Inc .'s tool kit deals include the January expansion of a partnership with Tel Aviv Sourasky Medical Center...
...Calif. Memorial Sloan Kettering Cancer Center, New York, N.Y. Seattle Children's Research Institute, Seattle, Wash. Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Feb 16, 2015
Company News

Kite Pharma, Tel Aviv Sourasky Medical Center deal

...The parties could not be reached for details. Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Nov 21, 2013
Tools & Techniques

Naive human iPS cells

...is a principal investigator at the Weizmann Institute. The paper also included researchers from the Tel Aviv Sourasky Medical Center...
...Gladstone Institute of Cardiovascular Disease , San Francisco, Calif. Harvard Medical School , Boston, Mass. Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Feb 1, 2010
Clinical News

CD24 blood test: Data

...Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancers meeting in Orlando. Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Jan 28, 2010
Distillery Therapeutics

Indication: Cancer

...et al. J. Natl. Cancer Inst.; published online Jan. 12, 2010; doi:10.1093/jnci/djp456 Contact: Ziv Gil, Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Nov 17, 2008
Company News

BioLineRx, Hebrew University of Jerusalem, Tel Aviv Sourasky Medical Center deal

...not disclosed. BioLineRx Ltd. (Tel Aviv:BLRX), Jerusalem, Israel Hebrew University of Jerusalem , Jerusalem, Israel Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Apr 2, 2007
Company News

BioLineRx, Tel-Aviv Sourasky Medical Center, Weizmann Institute of Science deal

BLRX received exclusive worldwide rights to develop and commercialize two preclinical therapeutic candidates. The institute and center’s BL-3040 is a selective estrogen receptor modulator to treat estrogen-regulated malignancies and osteoporosis. The institute’s BL-3050 is a...
Read More
Items per page:
1 - 7 of 7
BioCentury | Jun 8, 2015
Strategy

Juno's progressive thinking

...Kite Pharma Inc .'s tool kit deals include the January expansion of a partnership with Tel Aviv Sourasky Medical Center...
...Calif. Memorial Sloan Kettering Cancer Center, New York, N.Y. Seattle Children's Research Institute, Seattle, Wash. Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Feb 16, 2015
Company News

Kite Pharma, Tel Aviv Sourasky Medical Center deal

...The parties could not be reached for details. Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Nov 21, 2013
Tools & Techniques

Naive human iPS cells

...is a principal investigator at the Weizmann Institute. The paper also included researchers from the Tel Aviv Sourasky Medical Center...
...Gladstone Institute of Cardiovascular Disease , San Francisco, Calif. Harvard Medical School , Boston, Mass. Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Feb 1, 2010
Clinical News

CD24 blood test: Data

...Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancers meeting in Orlando. Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Jan 28, 2010
Distillery Therapeutics

Indication: Cancer

...et al. J. Natl. Cancer Inst.; published online Jan. 12, 2010; doi:10.1093/jnci/djp456 Contact: Ziv Gil, Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Nov 17, 2008
Company News

BioLineRx, Hebrew University of Jerusalem, Tel Aviv Sourasky Medical Center deal

...not disclosed. BioLineRx Ltd. (Tel Aviv:BLRX), Jerusalem, Israel Hebrew University of Jerusalem , Jerusalem, Israel Tel Aviv Sourasky Medical Center...
Read More
BioCentury | Apr 2, 2007
Company News

BioLineRx, Tel-Aviv Sourasky Medical Center, Weizmann Institute of Science deal

BLRX received exclusive worldwide rights to develop and commercialize two preclinical therapeutic candidates. The institute and center’s BL-3040 is a selective estrogen receptor modulator to treat estrogen-regulated malignancies and osteoporosis. The institute’s BL-3050 is a...
Read More
Items per page:
1 - 7 of 7